Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma

2013 ◽  
Vol 88 (5) ◽  
pp. 370-374 ◽  
Author(s):  
Jean El-Cheikh ◽  
Roberto Crocchiolo ◽  
Sabine Furst ◽  
Anne-Marie Stoppa ◽  
Patrick Ladaique ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Reduced Intensity Conditioning ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Reduced Intensity

scholarly journals Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma

2007 ◽  
Vol 13 (8) ◽  
pp. 925-931 ◽  
Author(s):  
John Kuruvilla ◽  
John D. Shepherd ◽  
Heather J. Sutherland ◽  
Thomas J. Nevill ◽  
Janet Nitta ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Term Outcome ◽  
Long Term Outcome

Death of frontline allo-SCT in myeloma

Blood ◽  
2012 ◽  
Vol 119 (26) ◽  
pp. 6178-6179 ◽  
Author(s):  
Philippe Moreau
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Reduced Intensity Conditioning ◽  
No Donor ◽  
Comparison Trial ◽  
Frontline Therapy ◽  
Reduced Intensity

In this issue of Blood, Lokhorst et al report the results of a donor versus no-donor comparison trial, which unambiguously establishes that reduced intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) should not be offered as part of frontline therapy in multiple myeloma (MM).1

Sign in / Sign up

Export Citation Format

Share Document